Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibito...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048921000339 |
| _version_ | 1819117982804082688 |
|---|---|
| author | Maria Tariq Siddiqui Allyson Price Alessandra Ferrajoli Gautam Borthakur |
| author_facet | Maria Tariq Siddiqui Allyson Price Alessandra Ferrajoli Gautam Borthakur |
| author_sort | Maria Tariq Siddiqui |
| collection | DOAJ |
| description | B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibitor, has had success in some patients with high risk features. Venetoclax, a BCL-2 inhibitor, has primarily been used in the relapsed setting. We present a case of B PLL with deletion 17p and mutated TP53 treated with ibrutinib and venetoclax in the frontline setting which resulted in measurable/minimal residual disease negative remission for approximately three years. |
| first_indexed | 2024-12-22T05:41:38Z |
| format | Article |
| id | doaj.art-2d8fc129dfff4383b6953837cca4d2de |
| institution | Directory Open Access Journal |
| issn | 2213-0489 |
| language | English |
| last_indexed | 2024-12-22T05:41:38Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj.art-2d8fc129dfff4383b6953837cca4d2de2022-12-21T18:37:10ZengElsevierLeukemia Research Reports2213-04892021-01-0116100266Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclaxMaria Tariq Siddiqui0Allyson Price1Alessandra Ferrajoli2Gautam Borthakur3Corresponding author.; The Department of Leukemia, MD Anderson Cancer Center, Houston, TX, United StatesThe Department of Leukemia, MD Anderson Cancer Center, Houston, TX, United StatesThe Department of Leukemia, MD Anderson Cancer Center, Houston, TX, United StatesThe Department of Leukemia, MD Anderson Cancer Center, Houston, TX, United StatesB cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibitor, has had success in some patients with high risk features. Venetoclax, a BCL-2 inhibitor, has primarily been used in the relapsed setting. We present a case of B PLL with deletion 17p and mutated TP53 treated with ibrutinib and venetoclax in the frontline setting which resulted in measurable/minimal residual disease negative remission for approximately three years.http://www.sciencedirect.com/science/article/pii/S2213048921000339B cell prolymphocytic leukemiaIbrutinibVenetoclaxDeletion 17pTP53 |
| spellingShingle | Maria Tariq Siddiqui Allyson Price Alessandra Ferrajoli Gautam Borthakur Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax Leukemia Research Reports B cell prolymphocytic leukemia Ibrutinib Venetoclax Deletion 17p TP53 |
| title | Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax |
| title_full | Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax |
| title_fullStr | Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax |
| title_full_unstemmed | Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax |
| title_short | Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax |
| title_sort | sustained mrd negative remission in del17p and tp53 mutated b cell prolymphocytic leukemia with ibrutinib and venetoclax |
| topic | B cell prolymphocytic leukemia Ibrutinib Venetoclax Deletion 17p TP53 |
| url | http://www.sciencedirect.com/science/article/pii/S2213048921000339 |
| work_keys_str_mv | AT mariatariqsiddiqui sustainedmrdnegativeremissionindel17pandtp53mutatedbcellprolymphocyticleukemiawithibrutinibandvenetoclax AT allysonprice sustainedmrdnegativeremissionindel17pandtp53mutatedbcellprolymphocyticleukemiawithibrutinibandvenetoclax AT alessandraferrajoli sustainedmrdnegativeremissionindel17pandtp53mutatedbcellprolymphocyticleukemiawithibrutinibandvenetoclax AT gautamborthakur sustainedmrdnegativeremissionindel17pandtp53mutatedbcellprolymphocyticleukemiawithibrutinibandvenetoclax |